Coherus Biosciences | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
AbbVie USD 3.29B 562M 2025-03
Acadia Pharmaceuticals USD 126.37M 3.71M 2025-03
ALKERMES USD 171.7M 24.71M 2025-03
Alnylam Pharmaceuticals USD 239.95M 55.39M 2025-03
Amarin USD 36.57M 397K 2025-03
Amgen USD 1.69B 191M 2025-03
Baxter International USD 703M 88M 2025-03
Biogen USD 572.5M 104.8M 2025-03
BioMarin Pharmaceutical USD 206.12M 50.65M 2025-03
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Eli Lilly USD 2.36B 62.3M 2025-03
Fujifilm JPY 195.51B 10.1B 2025-03
Gilead Sciences USD 1.26B 603M 2025-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Merck USD 2.53B 319M 2025-03
Myriad Genetics USD 135.7M 300K 2025-03
Pacira USD 86.78M 7.16M 2025-03
Perrigo USD 281.2M 46.4M 2025-03
Pfizer USD 3.01B 1.27B 2025-03
PTC Therapeutics USD 161.92M 77.24M 2025-03
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
Teva Pharmaceutical Industries USD 919M 33M 2025-03
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12
Xencor USD 17.34M 2.42M 2025-03
Zoetis USD 563M 62M 2025-03



Coherus Biosciences Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Jul 2025.